XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

Andy Gould, The Motley Fool

Sat, August 1, 2026 astatine 4:31 PM CDT 5 min read

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides wide vulnerability to the S&P 500 healthcare sector, whereas the Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) offers a targeted absorption connected biotechnology and pharmaceutical companies listed connected the Nasdaq.

Investors looking for healthcare vulnerability indispensable often take betwixt the stableness of a broad, diversified assemblage money versus the higher upside -- and higher volatility -- of a narrower, growth-oriented fund. This examination examines whether XLV's little costs and way grounds outweigh the concentrated risk-reward illustration of IBBQ.

Snapshot (cost & size)

Beta measures terms volatility comparative to the S&P 500; beta is calculated from monthly returns implicit the disposable money past (up to 5 years). The 1-year instrumentality represents full instrumentality implicit the trailing 12 months. Dividend output is the trailing-12-month organisation yield.

XLV is the little costly option, with an disbursal ratio of 0.08% compared to IBBQ's 0.19%. XLV besides pays a higher dividend output of 1.60% versus IBBQ's 0.79%.

Performance & hazard examination

This is wherever the 2 funds archer precise antithetic stories. IBBQ's 45.5% one-year instrumentality dwarfs what a wide healthcare money similar XLV typically delivers, but that show has travel with meaningfully larger swings on the way. A money concentrated successful biotech -- an manufacture driven by binary events similar FDA approvals, objective proceedings results, and patent cliffs -- volition mostly spot bigger peaks and valleys than a diversified portfolio that spans pharma giants, insurers, and aesculapian instrumentality makers. Investors chasing IBBQ's caller returns should spell successful with eyes wide unfastened to the drawdown hazard attached to that upside.

What's wrong

Launched successful 1998, XLV tracks the Health Care Select Sector Index, giving investors wide vulnerability to the healthcare manufacture wrong the S&P 500. The money holds 60 stocks spanning pharmaceuticals, aesculapian equipment, healthcare providers, and beingness sciences tools. Its largest positions see Eli Lilly (NYSE:LLY) astatine 16.5%, Johnson & Johnson (NYSE:JNJ) astatine 10.6%, and AbbVie (NYSE:ABBV) astatine 7.7%.

IBBQ tracks the Nasdaq Biotechnology Index, offering concentrated vulnerability to biotech and pharma companies trading connected the Nasdaq. It holds 251 stocks, led by Vertex Pharmaceuticals (NASDAQ:VRTX) astatine 8.1%, Amgen (NASDAQ:AMGN) astatine 7.9%, and Gilead Sciences (NASDAQ:GILD) astatine 6.9%. IBBQ was launched successful 2021.